Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) EBITDA Margin: 2021-2025

Historic EBITDA Margin for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to 11,953.49%.

  • Allogene Therapeutics' EBITDA Margin fell 5340251.00% to 11,953.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 25,140.81%, marking a year-over-year decrease of 77731919.00%. This contributed to the annual value of -1,166,927.27% for FY2024, which is 83188096.00% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' EBITDA Margin is 11,953.49%, which was down 37.22% from 19,041.42% recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' EBITDA Margin ranged from a high of 74,302.47% in Q4 2024 and a low of -401,533.33% during Q4 2023.
  • For the 3-year period, Allogene Therapeutics' EBITDA Margin averaged around -143,364.78%, with its median value being -132,311.89% (2023).
  • In the last 5 years, Allogene Therapeutics' EBITDA Margin slumped by 36,247,032bps in 2022 and then surged by 47,583,580bps in 2024.
  • Over the past 5 years, Allogene Therapeutics' EBITDA Margin (Quarterly) stood at -2.75% in 2021, then plummeted by 36,247,032bps to -362,473.08% in 2022, then plummeted by 3,906,026bps to -401,533.33% in 2023, then surged by 47,583,580bps to 74,302.47% in 2024, then plummeted by 5,340,251bps to 11,953.49% in 2025.
  • Its last three reported values are 11,953.49% in Q3 2025, 19,041.42% for Q2 2025, and 39,734.00% during Q1 2025.